Bertran, M. Teresa https://orcid.org/0000-0002-8336-0903
Walmsley, Robert https://orcid.org/0000-0003-3510-7214
Cummings, Thomas https://orcid.org/0000-0001-5214-9796
Aramburu, Iker Valle
Benton, Donald J. https://orcid.org/0000-0001-6748-9339
Mora Molina, Rocio https://orcid.org/0000-0001-7256-732X
Assalaarachchi, Jayalini https://orcid.org/0000-0002-6067-0845
Chasampalioti, Maria https://orcid.org/0000-0001-9782-3107
Swanton, Tessa https://orcid.org/0000-0003-1776-080X
Joshi, Dhira https://orcid.org/0000-0001-8660-2528
Federico, Stefania
Okkenhaug, Hanneke
Yu, Lu https://orcid.org/0000-0001-8378-9112
Oxley, David
Walker, Simon
Papayannopoulos, Venizelos https://orcid.org/0000-0002-3741-8190
Suga, Hiroaki https://orcid.org/0000-0002-5298-9186
Christophorou, Maria A. https://orcid.org/0000-0001-5455-7283
Walport, Louise J. https://orcid.org/0000-0002-3795-8365
Funding for this research was provided by:
Cancer Research UK (CC2030, CC2089)
RCUK | Medical Research Council (CC2030, CC2089)
Wellcome Trust (CC2030, CC2089)
Wellcome Trust (105642/Z/14/Z)
Wellcome Trust (SHWF 222825/Z/21/Z)
RCUK | Biotechnology and Biological Sciences Research Council (BBS/E/B/000C0421)
Article History
Received: 4 January 2024
Accepted: 15 October 2024
First Online: 11 November 2024
Competing interests
: M.T.B., R.W., T.C., M.A.C. and L.J.W. are inventors on UK Patent application No. 230979.0, which has been filed with respect to methods that modulate cellular reprogramming through enhancing the activity of the PADI4 enzyme. The remaining authors declare no competing interests.